<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://fn.bmj.com">
<title>Archives of Disease in Childhood - Fetal and Neonatal Edition current issue</title>
<link>http://fn.bmj.com</link>
<description>Archives of Disease in Childhood - Fetal and Neonatal Edition RSS feed -- current issue</description>
<prism:eIssn>1468-2052</prism:eIssn>
<prism:coverDisplayDate>Jan  1 2012 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Archives of Disease in Childhood - Fetal and Neonatal Edition</prism:publicationName>
<prism:issn>1359-2998</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F1?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F2?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F3?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F4?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F8?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F17?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F18?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F24?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F30?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F35?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F39?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F45?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F50?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F56?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F62?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F64?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F65?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F70?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F75-a?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F75-b?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F75-c?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F76-a?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F76-b?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F77-a?rss=1" />
  <rdf:li rdf:resource="http://fn.bmj.com/cgi/content/short/97/1/F77-b?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://hwmaint.fn.bmj.com/misc/home/ADC_95x60.gif" />
</channel>
<image rdf:about="http://hwmaint.fn.bmj.com/misc/home/ADC_95x60.gif">
<title>Archives of Disease in Childhood - Fetal and Neonatal Edition</title>
<url>http://hwmaint.fn.bmj.com/misc/home/ADC_95x60.gif</url>
<link>http://fn.bmj.com</link>
</image>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F1?rss=1">
<title><![CDATA[Highlights from this issue]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F1?rss=1</link>
<description><![CDATA[<sec id="s1"><st>Neonatal collapse</st><p>In November we published a paper on early neonatal sudden unexpected deaths<cross-ref type="bib" refid="R1">1</cross-ref> that made reference to the anticipated publication of the British Paediatric Survey Unit (BPSU) study on unexpected collapses in neonates. We now have this report. Becher <I>et al</I> present the BPSU data, accompanied by both an editorial and a letter. Intriguingly, the size of the birth cohorts in each paper was very similar (828 648 and 858 466, respectively), the main differences being that Leow collated data from a relatively small area over 25 years, while Becher used the whole of the UK and Eire over 13 months; and Becher's data were on the first 12 h while Leow looked at the first week. These rare but important events need careful investigation as detailed in the guidance from the British Association for Perinatal Medicine in March 2011: &lsquo;Guidelines for the Investigation of Newborn Infants...]]></description>
<dc:creator><![CDATA[Platt, M. W.]]></dc:creator>
<dc:date>2011-12-13T07:42:16-08:00</dc:date>
<dc:identifier>info:doi/10.1136/fetalneonatal-2011-301442</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;fetalneonatal-2011-301442</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Highlights from this issue]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Fantoms</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F1</prism:startingPage>
<prism:endingPage>F1</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F2?rss=1">
<title><![CDATA[Unexpected collapse of apparently healthy newborn infants: the benefits and potential risks of skin-to-skin contact]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F2?rss=1</link>
<description><![CDATA[<p>The routine separation of mothers and infants after delivery, a practice until recently very common in western midwifery and obstetric practice, may have significant negative effects on the establishment of normal mother&ndash;baby postnatal interactions, most importantly, the establishment of breast feeding.<cross-ref type="bib" refid="R1">1</cross-ref> Recognition of the importance of close and direct contact between mothers and babies in the period immediately after delivery has led to the widespread adoption of the practice of &lsquo;skin-to-skin&rsquo; care, in which the infant is placed naked and almost always prone directly onto the mother's chest very shortly after birth. The widely recognised potential benefits of early skin-to-skin contact, include improved prevalence and duration of breast feeding, improved maternal attachment behaviour and reduced crying by infants, together with improved cardiorespiratory stability for preterm infants.<cross-ref type="bib" refid="R1">1</cross-ref> The Cochrane review notes that this practice has &lsquo;no apparent short or long term negative effects&rsquo;.<cross-ref type="bib" refid="R1">1</cross-ref></p><p>The study by...]]></description>
<dc:creator><![CDATA[Fleming, P. J.]]></dc:creator>
<dc:date>2011-12-13T07:42:16-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300786</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300786</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Obstetrics and gynaecology, Smoking and tobacco, Epidemiologic studies, Neurological injury, Childhood nutrition, Reproductive medicine, Child health, Infant health, Infant nutrition (including breastfeeding), Neonatal health, Disability, Resuscitation, Trauma, Metabolic disorders, Health education, Injury, Health promotion, Smoking]]></dc:subject>
<dc:title><![CDATA[Unexpected collapse of apparently healthy newborn infants: the benefits and potential risks of skin-to-skin contact]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Editorials</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F2</prism:startingPage>
<prism:endingPage>F3</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F3?rss=1">
<title><![CDATA[Erythrocyte transfusions in neonates: is it safe to co-infuse dextrose-containing solutions?]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F3?rss=1</link>
<description><![CDATA[<p>Red blood cell (RBC) transfusions are an integral part of neonatal intensive care medicine.<cross-ref type="bib" refid="R1">1</cross-ref> We recently reported that 14% of patients admitted to the Intermountain Healthcare neonatal intensive care units (NICUs) receive one or more RBC transfusions and that the average transfused neonate receives 2.4 RBC transfusions during their stay in the NICU.<cross-ref type="bib" refid="R2">2</cross-ref></p><p>When a transfusion is administered to a newborn infant, the intravenous tubing through which the donor cells are infused is temporarily dedicated to this sole purpose. Specifically, during the 3 or 4 h the donor cells are infusing, no medications or other intravenous fluids are co-infused into the same tubing. When a neonate with only one intravenous tube needs a transfusion, a concern about hypoglycaemia during the transfusion raises the question whether a second intravenous tube should be started for infusion of a dextrose-containing solution. Because neonates needing a transfusion are often the smallest...]]></description>
<dc:creator><![CDATA[Christensen, R. D., Ilstrup, S.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300516</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300516</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Childhood nutrition, Childhood nutrition (paediatrics), Child health, Infant health, Infant nutrition (including breastfeeding), Neonatal and paediatric intensive care, Neonatal health, Neonatal intensive care, Diabetes, Metabolic disorders]]></dc:subject>
<dc:title><![CDATA[Erythrocyte transfusions in neonates: is it safe to co-infuse dextrose-containing solutions?]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Editorials</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F3</prism:startingPage>
<prism:endingPage>F3</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F4?rss=1">
<title><![CDATA[Recent changes to UK newborn resuscitation guidelines]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F4?rss=1</link>
<description><![CDATA[<p>The new UK newborn resuscitation guidelines were published online on the 18th of October 2010<cross-ref type="bib" refid="R1">1</cross-ref> simultaneously with the European guidelines.<cross-ref type="bib" refid="R2">2</cross-ref> Both are based upon evidence derived from a critical evaluation of relevant scientific publications over the preceding 5 years<cross-ref type="bib" refid="R3">3</cross-ref> <cross-ref type="bib" refid="R4">4</cross-ref> organised and co-ordinated by the International Liaison Committee on Resuscitation (ILCOR), with simultaneous publication of guidelines and evidence.<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3"></cross-ref><cross-ref type="bib" refid="R4"></cross-ref><cross-ref type="bib" refid="R5">5</cross-ref> This article summarises both the process and changes.</p><sec id="s1"><st>Changing guidelines via the ILCOR process</st><p>Representatives of the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada and the Resuscitation Council of South Africa founded the International Liaison Committee on Resuscitation (ILCOR) in 1992. Other organisations subsequently joined and in 1995 the task force of ILCOR established a neonatal subgroup. After the 2005 ILCOR publication,<cross-ref type="bib" refid="R6">6</cross-ref> this subgroup became an...]]></description>
<dc:creator><![CDATA[Wyllie, J.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300586</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300586</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Drugs: cardiovascular system, Stroke, Competing interests (ethics), Resuscitation, Arrhythmias, Guidelines]]></dc:subject>
<dc:title><![CDATA[Recent changes to UK newborn resuscitation guidelines]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Leading articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F4</prism:startingPage>
<prism:endingPage>F7</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F8?rss=1">
<title><![CDATA[Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F8?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To conduct a systematic review of the association between chorioamnionitis (CA) and bronchopulmonary dysplasia (BPD) in preterm infants.</p></sec><sec><st>Methods</st><p>The authors searched Medline, Embase, CINAHL, Science Citation Index and PubMed, reviewed reference lists and contacted the primary authors of relevant studies. Studies were included if they had a comparison group, examined preterm or low birthweight infants, and provided primary data. Two reviewers independently screened the search results, applied inclusion criteria and assessed methodological quality. One reviewer extracted data and a second reviewer checked data extraction. Studies were combined with an OR using a random effects model. Meta-regression was used to explore potential confounders.</p></sec><sec><st>Results</st><p>3587 studies were identified; 59 studies (15 295 patients) were included. The pooled unadjusted OR showed that CA was significantly associated with BPD (OR 1.89, 95% CI 1.56 to 2.3). Heterogeneity was substantial (I<sup>2</sup>=66.2%) and may be partially explained by the type of CA. Infants exposed to CA were significantly younger and lighter at birth. The pooled adjusted OR was 1.58 (95% CI 1.11 to 2.24); heterogeneity was substantial (I<sup>2</sup>=65.1%) which may be due to different variables being controlled in each study. There was strong evidence of publication bias which suggests potential overestimation of the measure of association between CA and BPD.</p></sec><sec><st>Conclusions</st><p>Unadjusted and adjusted analyses showed that CA was significantly associated with BPD; however, the adjusted results were more conservative in the magnitude of association. The authors found strong evidence of publication bias. Despite a large body of evidence, CA cannot be definitively considered a risk factor for BPD.</p></sec>]]></description>
<dc:creator><![CDATA[Hartling, L., Liang, Y., Lacaze-Masmonteil, T.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.210187</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.210187</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Bronchopulmonary dysplasia, Pregnancy, Child health, Infant health, Neonatal health]]></dc:subject>
<dc:title><![CDATA[Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F8</prism:startingPage>
<prism:endingPage>F17</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F17?rss=1">
<title><![CDATA[Intrauterine thrombosis of the ductus venosus leading to neonatal demise]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F17?rss=1</link>
<description><![CDATA[<p>A 36-year-old, gravida-3, para-2 presented with labour at the gestational age of 41 weeks. On admission, fetal monitoring was normal. It was discontinued for commodity, but after resuming (30 min later) there was significant fetal bradycardia. A rapid spontaneous vaginal delivery revealed meconium-stained amniotic fluid (grade III). No excessive fetal or placental blood loss was noted.</p><p>A female baby was born with APGAR scores of 1, 2 and 4 after 1, 5 and 10 min, respectively. She was intubated and given colloids, epinephrine, bicarbonate and calcium. Placement of an umbilical vein catheter was not possible because of resistance during placement of the catheter. An umbilical arterial blood gas showed a pH of 6.8. The infant was transported to a tertiary referral centre.</p><p>Upon arrival, the arterial blood gas revealed pH 6.99, pCO<SUB>2</SUB> 18.2 mm Hg, bicarbonate 4.2 mM and haemoglobin 4.9 g/dl. A central venous catheter was placed, packed cells were given,...]]></description>
<dc:creator><![CDATA[Witters, P., Reynaert, N., Pattyn, L., Vercammen, L., Claus, F., Debeer, A., Naulaers, G., Vanhole, C.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300024</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300024</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Journalology, Drugs: cardiovascular system, Drugs: CNS (not psychiatric), Pregnancy, Reproductive medicine, Child health, Competing interests (ethics), Arrhythmias]]></dc:subject>
<dc:title><![CDATA[Intrauterine thrombosis of the ductus venosus leading to neonatal demise]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Images in neonatal medicine</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F17</prism:startingPage>
<prism:endingPage>F17</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F18?rss=1">
<title><![CDATA[Randomised trial comparing hand expression with breast pumping for mothers of term newborns feeding poorly]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F18?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>Breast pumping or hand expression may be recommended when newborns latch or suck poorly. A recent trial found worse outcomes among mothers who used a breast pump in the early postpartum period. The objective of this study was to compare bilateral electric breast pumping to hand expression among mothers of healthy term infants feeding poorly at 12&ndash;36 h after birth.</p></sec><sec><st>Design</st><p>Randomised controlled trial.</p></sec><sec><st>Setting</st><p>Well-baby nursery and postpartum unit.</p></sec><sec><st>Patients</st><p>68 mothers of newborns 12&ndash;36 h old who were latching or sucking poorly were randomly assigned to either 15 min of bilateral electric pumping or 15 min of hand expression.</p></sec><sec><st>Mainoutcome measures</st><p>Milk transfer, maternal pain, breastfeeding confidence and breast milk expression experience (BMEE) immediately after the intervention, and breastfeeding rates at 2 months after birth.</p></sec><sec><st>Results</st><p>The median volume of expressed milk (range) was 0.5 (0&ndash;5) ml for hand expressing mothers and 1 (0&ndash;40) ml for pumping mothers (p=0.07). Maternal pain, breastfeeding confidence and BMEE did not differ by intervention. At 2 months, mothers assigned to hand expression were more likely to be breastfeeding (96.1%) than mothers assigned to breast pumping (72.7%) (p=0.02).</p></sec><sec><st>Conclusions</st><p>Hand expression in the early postpartum period appears to improve eventual breastfeeding rates at 2 months after birth compared with breast pumping, but further research is needed to confirm this. However, in circumstances where either pumping or hand expression would be appropriate for healthy term infants 12&ndash;36 h old feeding poorly, providers should consider recommending hand expression.</p></sec>]]></description>
<dc:creator><![CDATA[Flaherman, V. J., Gay, B., Scott, C., Avins, A., Lee, K. A., Newman, T. B.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.209213</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.209213</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Clinical trials (epidemiology), Press releases, Pain (neurology), Childhood nutrition, Reproductive medicine, Infant nutrition (including breastfeeding)]]></dc:subject>
<dc:title><![CDATA[Randomised trial comparing hand expression with breast pumping for mothers of term newborns feeding poorly]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F18</prism:startingPage>
<prism:endingPage>F23</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F24?rss=1">
<title><![CDATA[Efficacy of tramadol versus fentanyl for postoperative analgesia in neonates]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F24?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To assess, in newborn infants submitted to surgical procedures, the efficacy of two opioids&mdash;fentanyl and tramadol&mdash;regarding time to extubate, time to achieve 100 ml/kg of enteral feeding and pain in the first 72 h after surgery.</p></sec><sec><st>Design</st><p>Controlled, blind, randomised clinical trial.</p></sec><sec><st>Setting</st><p>Neonatal intensive care unit.</p></sec><sec><st>Patients</st><p>160 newborn infants up to 28 days of life requiring major or minor surgeries.</p></sec><sec><st>Interventions</st><p>Patients were randomised to receive analgesia with fentanyl (1&ndash;2 &mu;g/kg/h intravenously) or tramadol (0.1&ndash;0.2 mg/kg/h intravenously) in the first 72 h of the postoperative period, stratified by surgical size and by patient's gender.</p></sec><sec><st>Main outcome measures</st><p>Pain assessed by validated neonatal scales (Crying, Requires oxygen, Increased vital signs, Expression and Sleepless Scale and the Neonatal Facial Coding System), time until extubation and time to reach 100 ml/kg enteral feeding. Statistical analysis included repeated measures analysis of variance adjusted for confounding variables and Kaplan&ndash;Meier curve adjusted by a Cox model of proportional risks.</p></sec><sec><st>Results</st><p>Neonatal characteristics were (mean&plusmn;SD) birth weight of 2924&plusmn;702 g, gestational age of 37.6&plusmn;2.2 weeks and age at surgery of 199&plusmn;63 h. The main indication of surgery was gastrointestinal malformation (85 newborns; 53%). Neonates who received fentanyl or tramadol were similar regarding time until extubation, time to reach 100 ml/kg of enteral feeding and pain scores in the first 72 h after surgery.</p></sec><sec><st>Conclusion</st><p>Tramadol was as effective as fentanyl for postoperative pain relief in neonates but does not appear to offer advantages over fentanyl regarding the duration of mechanical ventilation and time to reach full enteral feeding.</p></sec><sec><st>Trial registration</st><p>NCT00713726</p></sec>]]></description>
<dc:creator><![CDATA[Alencar, A. J. C., Sanudo, A., Sampaio, V. M. R., Gois, R. P., Benevides, F. A. B., Guinsburg, R.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.203851</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.203851</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Surgery, Pain (neurology), Pain (palliative care), Pain (anaesthesia), Mechanical ventilation]]></dc:subject>
<dc:title><![CDATA[Efficacy of tramadol versus fentanyl for postoperative analgesia in neonates]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F24</prism:startingPage>
<prism:endingPage>F29</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F30?rss=1">
<title><![CDATA[Unexpected collapse in apparently healthy newborns - a prospective national study of a missing cohort of neonatal deaths and near-death events]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F30?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Sudden and unexpected postnatal collapse (SUPC) of a healthy newborn infant is a rare event, which carries a high risk of mortality and significant neurodisability in survivors. An underlying condition can be found in 60% of cases who undergo detailed postmortem but in the remainder there are important associations with prone position, breast feeding and primiparous status. The authors undertook a prospective study to ascertain the population incidence of SUPC in the UK.</p></sec><sec><st>Methods</st><p>Cases were referred through the British Paediatric Surveillance Unit reporting scheme over a 13-month period. Infants were at &ge;37 weeks of gestation, had an Apgar score of &ge;8 at 5 min, collapsed within 12 h in hospital requiring positive pressure ventilation and either died or received ongoing intensive care. Data were collected on maternal and infant characteristics, clinical investigations and 1-year outcome.</p></sec><sec><st>Findings</st><p>45 cases were reported, an incidence of 0.05/1000 live births of whom 12 infants died. In 15/45 infants, an underlying disease/abnormality was determined. In 30/45 cases (0.035/1000 live births), no such cause was found, but in 24, the clinical/pathological diagnosis was airway obstruction during breast feeding or in prone position. Mothers were commonly primiparous and unattended by clinical staff before collapse was recognised. Approach to investigation was highly disparate and frequently very limited. Of the 30 infants with no underlying disease/abnormality, 22 (73%) developed a postasphyxial encephalopathy and 10 had a poor outcome (33%) &ndash; 5 died and 5 had neurological sequelae at 1 year.</p></sec><sec><st>Interpretation</st><p>SUPC is rare in any one centre and there is no standard approach to investigation. In those cases where collapse is not due to an underlying abnormality, breast feeding and prone position are important associations. Guidelines for safe postnatal care of infants should include appropriate vigilance of infants particularly where mothers are primiparous or where ability to assess the baby may be impaired.</p></sec>]]></description>
<dc:creator><![CDATA[Becher, J.-C., Bhushan, S. S., Lyon, A. J.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.208736</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.208736</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Epidemiologic studies, Editor's choice, Childhood nutrition, Reproductive medicine, Child health, Infant nutrition (including breastfeeding), Neonatal and paediatric intensive care, Neonatal health, Disability]]></dc:subject>
<dc:title><![CDATA[Unexpected collapse in apparently healthy newborns - a prospective national study of a missing cohort of neonatal deaths and near-death events]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F30</prism:startingPage>
<prism:endingPage>F34</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F35?rss=1">
<title><![CDATA[Echocardiographic assessment of ductal significance: retrospective comparison of two methods]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F35?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Patent ductus arteriosus (PDA) in preterm infants is often assessed with echocardiographic parameters, especially colour Doppler ductal diameter and pulsed Doppler flow pattern. Clinical algorithms have been proposed in which PDA treatment is indicated by either large diameter or a particular flow pattern, however it is unknown whether ductal diameter and flow pattern provide equivalent stratification of infants.</p></sec><sec><st>Aim</st><p>Retrospectively assess both parameters in 197 echocardiograms from 104 infants (gestational age &lt;31 weeks).</p></sec><sec><st>Methods</st><p>Echocardiograms were independently reviewed and the internal colour Doppler diameter of the PDA and the pulsed Doppler flow pattern were characterised for each study (169 records had both parameters recorded).</p></sec><sec><st>Results</st><p>Diameter varied widely within each group but was significantly associated with flow pattern: mean diameter was greatest in the pulmonary hypertension (PH) group (2.6 mm), progressively narrowed across growing and pulsatile groups, and was smallest in the closing group (1.3 mm). When echocardiograms were categorised using previously published diameters, 82.4% of the PH group had diameters &gt;2.0 mm, large diameters predominated in the growing and pulsatile groups but to a progressively smaller extent, and 98.1% of closing group had diameters &lt;2.0 mm.</p></sec><sec><st>Conclusion</st><p>Ductal diameter and flow patterns are significantly associated, consistent with a narrowing of the ductus until closure. Overall, the two parameters are in good agreement but will result in different treatment decisions in some cases. Clinicians might consider using both methods as a cross check against each other, to assist in the management of preterm infants with a clinically detectable PDA.</p></sec>]]></description>
<dc:creator><![CDATA[Condo, M., Evans, N., Bellu, R., Kluckow, M.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.207233</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.207233</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Congenital heart disease, Echocardiography, Hypertension, Child health, Infant health, Neonatal health, Radiology, Clinical diagnostic tests, Radiology (diagnostics)]]></dc:subject>
<dc:title><![CDATA[Echocardiographic assessment of ductal significance: retrospective comparison of two methods]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F35</prism:startingPage>
<prism:endingPage>F38</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F39?rss=1">
<title><![CDATA[Outcomes following the surgical ligation of the patent ductus arteriosus in premature infants in Scotland]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F39?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To determine morbidity, mortality and associated risk factors following patent ductus arteriosus (PDA) ligation in premature infants.</p></sec><sec><st>Methods</st><p>Retrospective case note audit of premature infants referred to a national paediatric cardiothoracic surgical service (2001&ndash;2007) with univariate and multivariate analysis of potential risk factors for mortality and morbidity.</p></sec><sec><st>Results</st><p>125 infants were enrolled (median gestational age 26 weeks (IQR 25&ndash;27 weeks), median birth weight 840 g (IQR 730&ndash;1035 g)). Referral characteristics were median LA:Ao 1.8 (IQR 1.5&ndash;2.0), 80% ventilated, 18.4% continuous positive airway pressure, 70% diuretics and 58% prior treatment with cyclooxygenase inhibitors (COIs). Median age at PDA ligation was 31 days (IQR 25&ndash;41 days). Postoperative characteristics were median time to extubation 5 days (IQR 3&ndash;10 days), 36.0% corticosteroids, 46.8% domiciliary oxygen and 4.8% vocal cord palsy. The 30-day and 1-year mortality rates were 4.8% and 12.8%, respectively, with neurodisability in 32% of survivors. All deaths occurred in the ventilated group and were mainly attributable to bronchopulmonary dysplasia (BPD). Gestation and fractional inspired oxygen (FiO<SUB>2</SUB>)&gt;60% were significantly associated with 30-day mortality. FiO<SUB>2</SUB>, ventilation, lack of prior COIs and postoperative corticosteroids were significantly associated with 1-year mortality. Preoperative FiO<SUB>2</SUB>&gt;40% and lack of prior COIs retained independent significance for death at 1 year.</p></sec><sec><st>Conclusions</st><p>PDA ligation is well tolerated, with evidence of early benefit. The incidence of neurodisability or death from BPD at 1 year remains high. Increasing preoperative FiO<SUB>2</SUB> and lack of prior treatment with COIs are associated with increased mortality at 1 year.</p></sec>]]></description>
<dc:creator><![CDATA[Heuchan, A. M., Hunter, L., Young, D.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.206052</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.206052</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Bronchopulmonary dysplasia, Epidemiologic studies, Congenital heart disease, Child health, Infant health, Neonatal health, Disability, Ear, nose and throat/otolaryngology]]></dc:subject>
<dc:title><![CDATA[Outcomes following the surgical ligation of the patent ductus arteriosus in premature infants in Scotland]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F39</prism:startingPage>
<prism:endingPage>F44</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F45?rss=1">
<title><![CDATA[An association between infantile haemangiomas and erythropoietin treatment in preterm infants]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F45?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Infantile haemangiomas are benign vascular neoplasms that occur frequently in premature infants. The authors hypothesised that in addition to gestational age and birth weight, erythropoietin therapy may influence the incidence of these soft tissue tumours in preterm infants.</p></sec><sec><st>Methods</st><p>2563 infants born prematurely and admitted to the Division of Neonatology, University of Heidelberg Medical School were investigated in a retrospective analysis. Hospital charts for all infants were reviewed for clinical data. The primary endpoint was the percentage of infants who had received erythropoietin treatment and were diagnosed with a haemangioma.</p></sec><sec><st>Results</st><p>Haemangiomas were diagnosed in 4.3% (n=110) of the 2563 preterm infants. These 110 infants had a median gestational age of 29 weeks (IQR 27&ndash;33 weeks) and the female:male ratio was 1.8:1. A higher incidence of haemangiomas (12&ndash;15%) was detected in premature infants with a lower gestational age (&lt;31 weeks). Erythropoietin therapy was shown to be an independent risk factor after adjusting for all other known factors and oxygen therapy in multivariable analysis (HR 2.82, 95% CI 1.55 to 5.12). Subgroup analysis revealed that the effect was more pronounced in male than female infants (HR 3.61, 95% CI 1.52 to 8.57).</p></sec><sec><st>Conclusions</st><p>This retrospective study demonstrates that erythropoietin treatment is associated with an increase in the incidence of these benign vascular tumours after adjusting for all other factors.</p></sec>]]></description>
<dc:creator><![CDATA[Doege, C., Pritsch, M., Fruhwald, M. C., Bauer, J.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.187344</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.187344</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Oncology, Drugs: cardiovascular system, Child health, Infant health, Neonatal health, Drugs: endocrine system]]></dc:subject>
<dc:title><![CDATA[An association between infantile haemangiomas and erythropoietin treatment in preterm infants]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F45</prism:startingPage>
<prism:endingPage>F49</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F50?rss=1">
<title><![CDATA[European perspective on the diagnosis and treatment of posthaemorrhagic ventricular dilatation]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F50?rss=1</link>
<description><![CDATA[<sec><st>Background</st><p>Posthaemorrhagic ventricular dilatation (PHVD) is a serious complication of prematurity with subsequent disabilities. The diagnostic and therapeutic approaches to PHVD vary among neonatal centres.</p></sec><sec><st>Aim</st><p>To gain more insight into the different diagnostic criteria and treatment policies on PHVD among neonatal intensive care units across Europe.</p></sec><sec><st>Methods</st><p>A PHVD questionnaire was designed and sent to neonatologists in 37 European centres.</p></sec><sec><st>Results</st><p>A response was obtained from 32/37 (86%) centres located in 17 European countries. An overall estimated incidence of 7% was reported for severe intraventricular haemorrhages (grades III or IV according to Papile) among premature neonates born below 30 weeks&rsquo; gestation. Approximately half of these infants developed PHVD, of whom three-quarters required intervention. Ultrasound measurements of ventricular size were most commonly used to diagnose PHVD (94%). No consensus existed on which ventricular parameters needed to be enlarged and when to start treatment of PHVD. Early intervention (ie, initiated after the ventricular index (VI) exceeded the 97th percentile (p97) according to Levene) was provided in 8/32 centres (25%), whereas 23/32 centres (72%) first started therapy once the VI had crossed the p97+4 mm line and/or when neonates presented with a progressive increase in head circumference or with clinical symptoms of raised intracranial pressure. Wide variation was seen with respect to the applied therapy modalities for cerebrospinal fluid drainage.</p></sec><sec><st>Conclusion</st><p>This survey shows that diagnostic and therapeutic approaches to neonates with PHVD vary considerably. Uniform diagnostic criteria would facilitate studies to assess optimal timing and mode of intervention.</p></sec>]]></description>
<dc:creator><![CDATA[Brouwer, A., Brouwer, M., Groenendaal, F., Benders, M., Whitelaw, A., de Vries, L.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.207837</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.207837</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Radiology, Clinical diagnostic tests, Radiology (diagnostics)]]></dc:subject>
<dc:title><![CDATA[European perspective on the diagnosis and treatment of posthaemorrhagic ventricular dilatation]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F50</prism:startingPage>
<prism:endingPage>F55</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F56?rss=1">
<title><![CDATA[Enteral feeding practices in very preterm infants: an international survey]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F56?rss=1</link>
<description><![CDATA[<sec><st>Objective</st><p>To evaluate enteral feeding practices in neonatal units in different countries and on different continents.</p></sec><sec><st>Design</st><p>A web-based survey of 127 tertiary neonatal intensive care units in Australia, Canada, Denmark, Ireland, New Zealand, Norway, Sweden and the UK.</p></sec><sec><st>Results</st><p>124 units (98%) responded. 59 units (48%) had a breast milk bank or access to donor human milk (Australia/New Zealand 2/27, Canada 6/29, Scandinavia 20/20 and UK/Ireland 31/48). The proportion of units initiating enteral feeding within the first 24 h of life was: 43/124 (35%) if gestational age (GA) &lt;25 weeks, 53/124 (43%) if GA 25&ndash;27 weeks and 88/124 (71%) if GA 28&ndash;31 weeks. In general, Scandinavian units introduced enteral feeds the earliest, followed by UK/Ireland. Continuous feeding was routinely used for infants below 28 weeks' gestation in almost half of the Scandinavian units and in approximately one sixth of units in UK/Ireland, but rarely in Australia/New Zealand and Canada. Minimal enteral feeding for 4&ndash;5 days was common in Canada, but rare in Scandinavia. Target enteral feeding volume in a &lsquo;stable&rsquo; preterm infant was 140&ndash;160 ml/kg/day in most Canadian units and 161&ndash;180 ml/kg/day or higher in units in the other regions. There were also marked regional differences in criteria for use and timing when human milk fortifier was added.</p></sec><sec><st>Conclusions</st><p>This study highlights areas of uncertainty and demonstrates marked variability in feeding practices. It provides valuable data for planning collaborative feeding trials to optimise outcome in preterm infants.</p></sec>]]></description>
<dc:creator><![CDATA[Klingenberg, C., Embleton, N. D., Jacobs, S. E., O'Connell, L. A. F., Kuschel, C. A.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2010.204123</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2010.204123</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Child health, Infant health, Neonatal health]]></dc:subject>
<dc:title><![CDATA[Enteral feeding practices in very preterm infants: an international survey]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Original articles</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F56</prism:startingPage>
<prism:endingPage>F61</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F62?rss=1">
<title><![CDATA[Effect of co-infusion of dextrose-containing solutions on red blood cell haemolysis during packed red cell transfusion]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F62?rss=1</link>
<description><![CDATA[<sec><st>Aim</st><p>Transfusion guidelines prohibit co-infusion of maintenance intravenous fluid solutions, with significant consequences for neonatal clinical care. This study investigated co-infusion&ndash;related haemolysis in an in vitro model closely resembling clinical practice.</p></sec><sec><st>Methods</st><p>Packed red blood cells (PRBCs, n=8) were co-infused at 5 and 10 ml/h with dextrose 5%, 10% and intravenous amino acid solution (synthamin). Free haemoglobin (fHb), as a measure of haemolysis, was measured by spectrophotometry and presented as % haemolysis and total fHb content (&micro;mol/l).</p></sec><sec><st>Results</st><p>Following co-infusion, there was no significant increase in PRBC haemolysis with either type of solution co-infused (p=0.82) or infusion rate (p=0.5). Neither macroscopic nor microscopic agglutination was observed during co-infusion for any type of solution co-infused.</p></sec><sec><st>Conclusions</st><p>Co-infusion does not result in increased haemolysis, with total fHb significantly lower than currently accepted safe thresholds for fHb. Adherence to current guidelines may place undue restrictions on current transfusion practice in neonatal intensive care.</p></sec>]]></description>
<dc:creator><![CDATA[Stark, M. J., Story, C., Andersen, C.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300254</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300254</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Child health, Neonatal and paediatric intensive care, Neonatal health, Neonatal intensive care]]></dc:subject>
<dc:title><![CDATA[Effect of co-infusion of dextrose-containing solutions on red blood cell haemolysis during packed red cell transfusion]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Short reports</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F62</prism:startingPage>
<prism:endingPage>F64</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F64?rss=1">
<title><![CDATA[Aqueous 2% chlorhexidine-induced chemical burns in an extremely premature infant]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F64?rss=1</link>
<description><![CDATA[<p>Chlorhexidine gluconate 2.0% w/v aqueous solution (AquiHex 2%) was used to prepare the skin before umbilical catheter insertion soon after birth in a non-identical preterm twin born at 25+4 weeks gestation. Two hours later, the skin in the right iliac fossa, right flank, the periumbilical area, perineum and groin turned erythematous. Over the subsequent 6 h, the skin became pale (<cross-ref type="fig" refid="F1">figure 1</cross-ref>). The epithelium was lost in the affected areas, and the appearance was consistent with mixed-depth, partial-thickness burns. These injuries completely healed with conservative management over 4 weeks with no residual scarring. Interestingly, the other twin, who also needed umbilical catheter placement, did not develop any burns as the antiseptic solution was entirely wiped off with normal saline immediately after skin sterilisation.</p><p>Burns due to alcohol-based chlorhexidine (Chx) solutions have been reported in neonates.<cross-ref type="bib" refid="R1">1</cross-ref><cross-ref type="bib" refid="R2">&ndash;</cross-ref><cross-ref type="bib" refid="R3">3</cross-ref> To the best of our knowledge, there are...]]></description>
<dc:creator><![CDATA[Lashkari, H. P., Chow, P., Godambe, S.]]></dc:creator>
<dc:date>2011-12-13T07:42:17-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2011.215145</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2011.215145</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:subject><![CDATA[Journalology, Drugs: infectious diseases, Child health, Infant health, Neonatal health, Trauma, Injury]]></dc:subject>
<dc:title><![CDATA[Aqueous 2% chlorhexidine-induced chemical burns in an extremely premature infant]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Images in neonatal medicine</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F64</prism:startingPage>
<prism:endingPage>F64</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F65?rss=1">
<title><![CDATA[Monitoring of seizures in the newborn]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F65?rss=1</link>
<description><![CDATA[<p>Neonatal seizures are a distinct and not uncommon sign of neurological disease in the newborn, most often occurring in association with hypoxic-ischaemic encephalopathy at term. The diagnosis and monitoring of seizures in the newborn is a considerable challenge, with many suspected clinical seizures having no electrographic correlates, while many electrographic seizures have no clinical correlate. Continuous video-EEG is the gold standard for seizure monitoring, but few centres have the resources or expertise required. Amplitude-integrated EEG can be a helpful monitoring tool in experienced hands, but has potential for error when used by inexperienced staff. Automated seizure detection algorithms show much promise and some cotside systems are already available. The efficiency and accuracy of these systems is likely to improve.</p>]]></description>
<dc:creator><![CDATA[Shah, D. K., Boylan, G. B., Rennie, J. M.]]></dc:creator>
<dc:date>2011-12-13T07:42:18-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2009.169508</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2009.169508</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Monitoring of seizures in the newborn]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Reviews</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F65</prism:startingPage>
<prism:endingPage>F69</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F70?rss=1">
<title><![CDATA[Should the use of probiotics in the preterm be routine?]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F70?rss=1</link>
<description><![CDATA[<p>Does the clinical trials' evidence of benefit justify the routine use of probiotics in the preterm infant? There are many uncertainties surrounding the use of probiotics in the preterm, including the mechanism(s) of action of probiotics, knowledge of who benefits and who might not, whether it is placement of large numbers of bacteria into the small intestine or colonisation that determines efficacy, the forms of microbial adaptation(s) and ecological consequences. There is also a current lack of defined products with associated evidence of safety in the preterm infant. It is argued that one cannot assume safety because of a lack of evidence of harm and that one should take a precautionary approach to the introduction of probiotics into routine neonatal practice. One should also consider how best one might monitor microbiological and ecological consequences and longer-term health outcomes before the introduction of this novel intervention into routine practice.</p>]]></description>
<dc:creator><![CDATA[Millar, M., Wilks, M., Fleming, P., Costeloe, K.]]></dc:creator>
<dc:date>2011-12-13T07:42:18-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2009.178939</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2009.178939</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Should the use of probiotics in the preterm be routine?]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>Reviews</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F70</prism:startingPage>
<prism:endingPage>F74</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F75-a?rss=1">
<title><![CDATA[Empirical antibiotics for suspected early neonatal sepsis]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F75-a?rss=1</link>
<description><![CDATA[<p>&lsquo;Empirical treatment of neonatal sepsis: are the current guidelines adequate?&rsquo;<cross-ref type="bib" refid="R1">1</cross-ref> makes recommendations for empirical antibiotic treatment of neonates based on voluntary surveillance data relating to blood culture isolates. The adverse effects of antibiotic treatment do not appear to have been considered and the recommendations do not differentiate between early and late sepsis.</p><p>In 2010, the NPSA (National Patient Safety Agency) reported that, over a 1-year period, 507 incidents involving gentamicin treatment of neonates were notified,<cross-ref type="bib" refid="R2">2</cross-ref> 23 of which resulted in &lsquo;moderate harm&rsquo; in the short term with additional possible longer-term adverse outcomes of cochlear or vestibular damage. It is also known that the m.1555A-&gt;G mutation occurs in a proportion of the population and was shown to have a frequency of 0.19% in a large UK cohort, giving significant genetic susceptibility to the toxic effects of the aminoglycosides, with a high risk of permanent cochlear damage following normal...]]></description>
<dc:creator><![CDATA[Hall, M. A., Wain, S., Pallett, A., Faust, S. N.]]></dc:creator>
<dc:date>2011-12-13T07:42:18-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300152</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300152</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Empirical antibiotics for suspected early neonatal sepsis]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F75</prism:startingPage>
<prism:endingPage>F75</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F75-b?rss=1">
<title><![CDATA[Breast feeding and unexpected neonatal and infant death]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F75-b?rss=1</link>
<description><![CDATA[<p>The paper by Becher <I>et al</I> that analysed cases of unexpected collapse in previously healthy newborns reported to the British Paediatric Surveillance Unit over a 13 month period provides valuable information on the range of potentially lethal conditions in this age group that may remain unsuspected until collapse.<cross-ref type="bib" refid="R1">1</cross-ref> Of concern was the high percentage (24/45; 53%) of cases identified where the episodes were attributed to airway obstruction associated with breast feeding, skin-to-skin or the prone position. While there is no denying the importance of breast feeding, it is equally important to recognise that situations may arise where certain infants may suffer lethal airway obstruction while feeding. This problem was reported a number of years ago now, not only in neonates in hospital but also in infants up to 9 weeks of age.<cross-ref type="bib" refid="R2">2</cross-ref> Following the publication of this paper a number of colleagues described similar cases to...]]></description>
<dc:creator><![CDATA[Byard, R. W.]]></dc:creator>
<dc:date>2011-12-13T07:42:18-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300804</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300804</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Breast feeding and unexpected neonatal and infant death]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F75</prism:startingPage>
<prism:endingPage>F75</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F75-c?rss=1">
<title><![CDATA[Empirical antibiotics for suspected early neonatal sepsis]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F75-c?rss=1</link>
<description><![CDATA[<p>In responding to the article by Muller-Pebody and colleagues,<cross-ref type="bib" refid="R1">1</cross-ref> Michael Hall and colleagues<cross-ref type="bib" refid="R2">2</cross-ref> report that they use empiric cefotaxime monotherapy for suspected neonatal sepsis, contrary to the UK national guidelines, because they are concerned about aminoglycoside toxicity. They also state wrongly that the authors do not distinguish early- from late-onset sepsis.</p><p>The concerns about aminoglycoside toxicity in neonates are largely theoretical, because there is virtually no evidence of normal aminoglycoside dosing causing significant hearing impairment in neonates.<cross-ref type="bib" refid="R3">3</cross-ref> The recommendation against cefotaxime monotherapy is based on three factors: selection of resistant organisms, particularly extended-spectrum &beta;-lactamase (ESBL) producing organisms, selection of organisms that are intrinsically resistant to cefotaxime particularly enterococci and increased incidence of invasive fungal infection (IFI).<cross-ref type="bib" refid="R4">4</cross-ref> Hall reports that 0.68% of their very low birthweight babies developed IFI, but according to one case control study,<cross-ref type="bib" refid="R3">3</cross-ref> their rate of IFI might have...]]></description>
<dc:creator><![CDATA[Isaacs, D.]]></dc:creator>
<dc:date>2011-12-13T07:42:18-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300923</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300923</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Empirical antibiotics for suspected early neonatal sepsis]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F75</prism:startingPage>
<prism:endingPage>F76</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F76-a?rss=1">
<title><![CDATA[Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F76-a?rss=1</link>
<description><![CDATA[<p>Barzilay <I>et al</I><cross-ref type="bib" refid="R1">1</cross-ref> stated recently that oral ibuprofen is more effective than intravenous ibuprofen for patent ductus arteriosus (PDA) closure. They attribute this superiority to pharmacokinetics; maintaining therapeutic plasma levels over a longer time extending the drug's therapeutic effect.</p><p>In an attempt to support their conclusion, they compare ibuprofen area under the curve (AUC) 0-&gt;24 generated by their study with data generated by two studies of intravenous ibuprofen.<cross-ref type="bib" refid="R2">2</cross-ref> <cross-ref type="bib" refid="R3">3</cross-ref> This explanation of oral ibuprofen superiority is problematic from several perspectives. First, none of the studies directly compared intravenous with oral ibuprofen. Thus, the data contrasts results obtained from different populations, using different study protocols and methodology. As such, there is no way to know whether the differences are statistically or clinically significant. Furthermore, there is another study which looked at oral ibuprofen pharmacokinetics<cross-ref type="bib" refid="R4">4</cross-ref> and showed lower AUC 0-&gt;24 levels than either of the...]]></description>
<dc:creator><![CDATA[Amitai, Y., Hammerman, C.]]></dc:creator>
<dc:date>2011-12-13T07:42:18-08:00</dc:date>
<dc:identifier>info:doi/10.1136/fetalneonatal-2011-301204</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;fetalneonatal-2011-301204</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F76</prism:startingPage>
<prism:endingPage>F76</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F76-b?rss=1">
<title><![CDATA[Efficacy and safety of intravenous Ig and alterations in haematological parameters of infants with isoimmune haemolytic disease]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F76-b?rss=1</link>
<description><![CDATA[<p>Intravenous Ig (IVIg &ndash; polyclonal Ig) administration to neonates with Rhesus-mediated isoimmune haemolytic disease has been shown to decrease the need for exchange transfusion (number needed to treat=2.7).<cross-ref type="bib" refid="R1">1</cross-ref> The use of IVIg as an adjuvant treatment for neonatal sepsis has been extensively studied. A 2010 Cochrane systematic review of this application in preterm (&lt;37 weeks)/low birthweight (&lt;2500 g) infants analysed the results of 19 studies involving 5000 infants. The authors concluded that IVIg administration resulted in a 3&ndash;4% reduction in sepsis or serious infection but was not associated with decreased morbidity or mortality.<cross-ref type="bib" refid="R2">2</cross-ref> IVIg is postulated to interact and upregulate multiple immune function pathways. However, there is little research on neonatal immune function, especially in the preterm population.<cross-ref type="bib" refid="R3">3</cross-ref></p><p>A possible association between IVIg therapy and necrotising enterocolitis (NEC) has been suggested from population studies.<cross-ref type="bib" refid="R4">4</cross-ref> As phototherapy, exchange transfusion and active haemolysis are also...]]></description>
<dc:creator><![CDATA[Freyne, B., O'Hare, F. M., Molloy, E. J.]]></dc:creator>
<dc:date>2011-12-13T07:42:19-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300446</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300446</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Efficacy and safety of intravenous Ig and alterations in haematological parameters of infants with isoimmune haemolytic disease]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F76</prism:startingPage>
<prism:endingPage>F77</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F77-a?rss=1">
<title><![CDATA[Categorising neonatal transports]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F77-a?rss=1</link>
<description><![CDATA[<p>The UK is now covered by separately commissioned neonatal transport services. This has required significant investment and it is essential that meaningful comparisons of activity levels, outcomes and value for money be made.</p><p>The UK Neonatal Transport Interest Group devised a dataset in 2005 to compare transport teams. The major problem encountered was defining mutually exclusive categories of transfer. The terms &lsquo;planned&rsquo; and &lsquo;unplanned&rsquo; were agreed, with &lsquo;time-critical&rsquo; added following publication of the Neonatal Toolkit.<cross-ref type="bib" refid="R1">1</cross-ref> Unplanned/time-critical transfers are subject to scrutiny as part of the Neonatal Quality Standards.<cross-ref type="bib" refid="R2">2</cross-ref> There is a wide variation between teams in the proportion of transfers that are classified as &lsquo;unplanned&rsquo;. In 2010, this ranged between teams from 23% of transfers to 63%.</p><p>Is this apparent disparity between teams due to a classification issue? We sent a questionnaire to transport service leads in the UK in December 2010, comprising 10 hypothetical transport scenarios. Respondents...]]></description>
<dc:creator><![CDATA[Leslie, A., Fenton, A.]]></dc:creator>
<dc:date>2011-12-13T07:42:19-08:00</dc:date>
<dc:identifier>info:doi/10.1136/archdischild-2011-300509</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;archdischild-2011-300509</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Categorising neonatal transports]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F77</prism:startingPage>
<prism:endingPage>F77</prism:endingPage>
</item>
<item rdf:about="http://fn.bmj.com/cgi/content/short/97/1/F77-b?rss=1">
<title><![CDATA[Hypoxic ischaemic encephalopathy: accuracy of the reported incidence]]></title>
<link>http://fn.bmj.com/cgi/content/short/97/1/F77-b?rss=1</link>
<description><![CDATA[<p>With national reporting and benchmarking of perinatal outcomes, it is essential that the criteria used to detect cases of hypoxic ischaemic encephalopathy (HIE) are robust.</p><p>The Neonatal Survey (TNS) is a validated survey collecting neonatal outcome data. Neonatal encephalopathy (NE) is used as a proxy measure of HIE; grade 2 NE cases require anticonvulsant therapy, grade 3 NE requiring either ventilation and anticonvulsant therapy (grade 3a) or ventilation following birth depression (grade 3b). Previous audits of the criteria suggest a false-positive rate of 10%.<cross-ref type="bib" refid="R1">1</cross-ref></p><p>Marked variations in the reported rates of HIE are seen in TNS, the rate in the Leeds Teaching Hospitals NHS Trust approaches six times that of other tertiary units. (Rate per 1000 live births (95% CI) 2007&ndash;2009, Leeds Hospital 3.4 (2.5 to 4.6), other tertiary unit 0.4 (0.2 to 0.8).)<cross-ref type="bib" refid="R1">1</cross-ref> This picture is at odds with our clinical experience. In order to further explore...]]></description>
<dc:creator><![CDATA[Yates, H. L., McCullough, S., Harrison, C., Gill, A. B.]]></dc:creator>
<dc:date>2011-12-13T07:42:19-08:00</dc:date>
<dc:identifier>info:doi/10.1136/adc.2011.301240</dc:identifier>
<dc:identifier>hwp:master-id:fetalneonatal;adc.2011.301240</dc:identifier>
<dc:publisher>BMJ Publishing Group</dc:publisher>
<dc:title><![CDATA[Hypoxic ischaemic encephalopathy: accuracy of the reported incidence]]></dc:title>
<prism:publicationDate>2012-01-01</prism:publicationDate>
<prism:section>PostScript</prism:section>
<prism:volume>97</prism:volume>
<prism:number>1</prism:number>
<prism:startingPage>F77</prism:startingPage>
<prism:endingPage>F78</prism:endingPage>
</item>
</rdf:RDF>
